Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLIC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLIC1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for binding assays. |
View CLIC1 Products |
| Gene Delivery | CLIC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and electrophysiology validation. |
View CLIC1 Products |
| Benchmark Ab | Anti-CLIC1 Recombinant Antibody Recombinant positive control for flow cytometry and functional blocking assays. |
View CLIC1 Products |
| Validator | CLIC1 siRNA Set For knockdown verification in functional validation assays. |
View CLIC1 Products |
| Related Target A | CLIC4 Subfamily homolog; crucial for off-target selectivity screening. |
View CLIC4 Products |
| Related Target B | ANO1 Alternative calcium-activated chloride channel associated with tumor progression. |
View ANO1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Metamorphic structural transition analysis | Highly stable soluble monomeric recombinant CLIC1 verified by SDS-PAGE and SEC-MALS. |
| Subfamily counter-screening (CLIC4/CLIC2) | Homology panel proteins strictly verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of reliable positive control antibodies | Sequence-verified clinical benchmark antibodies available as research-grade biosimilars. |
| False positives in phenotype screening | Sequence-validated siRNA pool included for target-specific knockdown verification. |
Live CLIC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLIC1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum ion channel blockers to highly selective monoclonal antibodies and targeted small molecules. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting the specific membrane-inserted state of CLIC1, which is selectively overexpressed in the tumor microenvironment under oxidative stress.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Channel Blockers | Academic/Biotech Consortiums | Glioblastoma, Pancreatic Cancer | Electrophysiology & Halide Flux Assays (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibodies | Oncology-focused Biotechs | Solid Tumors, Metastatic Cancers | Conformation-Specific Binding (Need High-Purity Recombinant Protein & Flow Cytometry Controls) |
| siRNA Therapeutics | RNAi Specialists | Refractory Glioblastoma | In vitro Knockdown Validation (Need Sequence-Validated siRNA Sets) |